日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors

FoundationOne CDx检测在晚期实体瘤患者治疗决策中的临床应用

期刊:Oncologist
影响因子:4.2
doi:10.1002/onco.13639
Takeda, Masayuki; Takahama, Takayuki; Sakai, Kazuko; Shimizu, Shigeki; Watanabe, Satomi; Kawakami, Hisato; Tanaka, Kaoru; Sato, Chihiro; Hayashi, Hidetoshi; Nonagase, Yoshikane; Yonesaka, Kimio; Takegawa, Naoki; Okuno, Tatsuya; Yoshida, Takeshi; Fumita, Soichi; Suzuki, Shinichiro; Haratani, Koji; Saigoh, Kazumasa; Ito, Akihiko; Mitsudomi, Tetsuya; Handa, Hisashi; Fukuoka, Kazuya; Nakagawa, Kazuhiko; Nishio, Kazuto
发表日期：2021
文献求助 收藏

Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer

格拉斯哥预后评分（GPS）和肿瘤反应作为纳武利尤单抗单药治疗晚期胃癌三线或后续治疗的生物标志物

期刊:In Vivo
影响因子:1.8
doi:10.21873/invivo.11989
Kurosaki, Takashi; Kawakami, Hisato; Mitani, Seiichiro; Kawabata, Ryohei; Takahama, Takayuki; Nonagase, Yoshikane; Fumita, Soichi; Ozaki, Tomohiro; Chiba, Yasutaka; Tamura, Takao; Nakagawa, Kazuhiko
胃癌
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer

5-氟尿嘧啶、多西他赛和奈达铂（UDON）联合疗法治疗复发或转移性食管癌的II期临床试验

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2018-0653
Ueda, Hiroto; Kawakami, Hisato; Nonagase, Yoshikane; Takegawa, Naoki; Okuno, Tatsuya; Takahama, Takayuki; Takeda, Masayuki; Chiba, Yasutaka; Tamura, Takao; Nakagawa, Kazuhiko
食管癌
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

基于知识的内容管理系统在癌症临床测序中的比较研究

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-019-47673-9
Sakai, Kazuko; Takeda, Masayuki; Shimizu, Shigeki; Takahama, Takayuki; Yoshida, Takeshi; Watanabe, Satomi; Iwasa, Tsutomu; Yonesaka, Kimio; Suzuki, Shinichiro; Hayashi, Hidetoshi; Kawakami, Hisato; Nonagase, Yoshikane; Tanaka, Kaoru; Tsurutani, Junji; Saigoh, Kazumasa; Ito, Akihiko; Mitsudomi, Tetsuya; Nakagawa, Kazuhiko; Nishio, Kazuto
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer

针对 HER2/HER3 信号轴可克服 HER2 阳性乳腺癌中配体介导的曲妥珠单抗耐药性

期刊:Cancer Medicine
影响因子:2.9
doi:10.1002/cam4.1995
Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
信号转导
肿瘤
乳腺癌
WB
发表日期：2019
文献求助 收藏

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer

EGFR 突变非小细胞肺癌酪氨酸激酶抑制剂治疗前后肿瘤组织和血浆 AXL 和 GAS6 水平

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.13166
Yoshikane Nonagase, Masayuki Takeda, Koichi Azuma, Hidetoshi Hayashi, Koji Haratani, Kaoru Tanaka, Kimio Yonesaka, Hidenobu Ishii, Tomoaki Hoshino, Kazuhiko Nakagawa
肿瘤
肺癌
其它细胞
IHC
发表日期：2019
文献求助 收藏

Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report

吉非替尼序贯奥希替尼治疗EGFR突变阳性非小细胞肺癌合并特鲁索综合征：病例报告

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.25687
Nonagase, Yoshikane; Takeda, Masayuki; Tanaka, Kaoru; Hayashi, Hidetoshi; Iwasa, Tsutomu; Nakagawa, Kazuhiko
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2018
文献求助 收藏

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

西妥昔单抗耐药性结直肠癌患者循环肿瘤DNA中HER2基因组扩增

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.6498
Takegawa, Naoki; Yonesaka, Kimio; Sakai, Kazuko; Ueda, Hiroto; Watanabe, Satomi; Nonagase, Yoshikane; Okuno, Tatsuya; Takeda, Masayuki; Maenishi, Osamu; Tsurutani, Junji; Satoh, Taroh; Okamoto, Isamu; Nishio, Kazuto; Tamura, Takao; Nakagawa, Kazuhiko
肿瘤
肠癌
肿瘤免疫
HER2
发表日期：2016
文献求助 收藏

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

表达赫格林（Heregulin）的HER2阳性乳腺癌和胃癌对HER2抑制剂拉帕替尼、曲妥珠单抗和T-DM1表现出异质性敏感性。

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.12743
Nonagase, Yoshikane; Yonesaka, Kimio; Kawakami, Hisato; Watanabe, Satomi; Haratani, Koji; Takahama, Takayuki; Takegawa, Naoki; Ueda, Hiroto; Tanizaki, Junko; Hayashi, Hidetoshi; Yoshida, Takeshi; Takeda, Masayuki; Chiba, Yasutaka; Tamura, Takao; Nakagawa, Kazuhiko; Tsurutani, Junji
胃癌
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2016
文献求助 收藏